

Special Issue

Tailored Molecular and Pathophysiological Approach to COVID-19: Ambition and Need

Message from the Guest Editor

Common to all SARS-CoV-2 variants is the direct damage to the subtle mechanisms of the renin-angiotensin system that presides over a large part of systemic inflammation and hemodynamics, i.e., the damage to ACE2 (the cell membrane viral receptor) and ACE2-driven angiotensin 1-7 production. Attempts at replacing defective ACE2 or angiotensin 1-7 functions during the clinical course of COVID-19 have been common and pursued all over the world. After two years of pandemic, a tailored and sensible approach to COVID-19 must include: a) a definition of the mechanisms of inflammatory disease that follow cellular infection; b) cognition of the most frequently found viral variants in terms of genomic and antigenic mutations; and c) identification of biomolecular viral and host targets, the latter being the non-classical renin-angiotensin system, that could be acted upon pharmacologically. These aims warrant renewed international and multi-disciplinary efforts.

Guest Editor

Dr. Sansoè Giovanni

Humanitas Institute, Gradenigo Hospital, Torino, Italy

Deadline for manuscript submissions

closed (31 August 2023)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/121032

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0

CiteScore 3.7

Indexed in PubMed



[mdpi.com/journal/
cimb](http://mdpi.com/journal/cimb)

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

